Anthony Bella is an outstanding urologic medical clinician and surgeon with a broad reputation for his knowledge and expertise in the Men’s Health sector that spans the globe
Ottawa, Ontario (PRWEB) September 11, 2015
VMS Rehab Systems Inc., (http://www.vmsrehabsystemsinc.com) reported today that Dr. Anthony Bella, a leading expert on urologic disorders in Men has agreed to serve as the Chief Medical Officer (CMO) for BioPharmcor (http://www.biopharmcor.com) , the Company’s early stage generic pharmaceutical business.
Headquarterd in Amsterdam, The Netherlands, BioPharmcor B.V. and its wholly owned Poland based subsidiary, BioPharmcor Sp.z o.o. are currently developing generic drug therapies for the treatment of ED (Erectile Dysfunction) and BPH (Benign Prostatic Hyperplasia).
In making this announcement, Michael S Wexler, Chairman, VMS Rehab Systems, Inc explains that “Anthony Bella is an outstanding urologic medical clinician and surgeon with a broad reputation for his knowledge and expertise in the Men’s Health sector that spans the globe. We are confident that Dr. Bella will provide the leadership required to build out a pipeline of generic drugs that will consolidate BioPharmcor’s market position in providing first line treatment for chronic urologic and Men's Health issues”.
In addition to his role as BioPharmcor’s Chief Medical Officer, Dr. Bella also serves as a Member of the Management Boards of both BioPharmcor BV, The Netherlands, and BioPharmcor Sp z o.o., Poland.
VMS Rehab Systems, Inc, is headquartered in Ottawa, Canada. In addition to its activities in the generic drugs business for advancing Men’s health, the Company also supplies home healthcare products throughout Canada (http://www.vmsrehabsystems.ca).
Shares of VMS Rehab Systems, Inc are listed on the US OTC Pink Current Market (Symbol: VRSYF)
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.